Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

319 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Unraveling the science of incretin biology.
Nauck MA. Nauck MA. Eur J Intern Med. 2009 Jul;20 Suppl 2:S303-8. doi: 10.1016/j.ejim.2009.05.012. Epub 2009 Jun 21. Eur J Intern Med. 2009. PMID: 19580949 Review.
The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.
El-Ouaghlidi A, Rehring E, Holst JJ, Schweizer A, Foley J, Holmes D, Nauck MA. El-Ouaghlidi A, et al. Among authors: nauck ma. J Clin Endocrinol Metab. 2007 Nov;92(11):4165-71. doi: 10.1210/jc.2006-1932. Epub 2007 Aug 14. J Clin Endocrinol Metab. 2007. PMID: 17698900 Clinical Trial.
Incretin-based therapies: viewpoints on the way to consensus.
Nauck MA, Vilsbøll T, Gallwitz B, Garber A, Madsbad S. Nauck MA, et al. Diabetes Care. 2009 Nov;32 Suppl 2(Suppl 2):S223-31. doi: 10.2337/dc09-S315. Diabetes Care. 2009. PMID: 19875556 Free PMC article. Review. No abstract available.
319 results